Effectiveness of annual flu vaccination until week four of season 2018/2019

Background: Annual flu vaccination is the most effective measure to prevent the disease and its complications. Vaccine effectiveness (EV) vanes from season to season, requiring annual re-evaluation. The objective of this work was to estimate the preliminary effectiveness of the influenza vaccine unt...

Descripción completa

Detalles Bibliográficos
Autores: Gras-Valenti, P, Algado-Selles, N, Chico-Sanchez, P, Cabrera-Tejada, GG, Rodriguez-Diaz, JC, Sanchez-Paya, J
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2019
País:España
Institución:Instituto de Investigación Biomédica y Sanitaria de Alicante (ISABIAL)
Repositorio:r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
OAI Identifier:oai:isabial.fundanetsuite.com:p5914
Acceso en línea:https://isabial.portalinvestigacion.com/publicaciones5914
Access Level:acceso abierto
Palabra clave:Influenza
Human
Vaccination
Influenza vaccines
Vaccination coverage
Treatment outcome
Descripción
Sumario:Background: Annual flu vaccination is the most effective measure to prevent the disease and its complications. Vaccine effectiveness (EV) vanes from season to season, requiring annual re-evaluation. The objective of this work was to estimate the preliminary effectiveness of the influenza vaccine until epidemiological week 4 of the 2018/2019 season, in patients admitted to a third level hospital. Methods: The Test Negative Design (TDN) was carried out at the Hospital General Umversitario de Alicante. Patients admitted with laboratory-confirmed influenza (RT-PCR positive for any influenza virus, in clinical sample of nasopharyngeal aspirate) and those with clinical suspicion of influenza and negative RT-PCR, from week 40 to week 4 of the 2018/2019 influenza season, were considered as controls. The vaccination coverage was calculated in the cases and in the controls, and the EV with its 95% confidence interval using the formula: EV = (1-Odds Ratio) x 100. Results: We included 524 patients: 58 cases and 466 controls. The overall EV for prevention of influenza cases was 42.5 % (95% CI -17.1 to 71.8) and for those over 1 year of age 63.7 % (95% CI 25.4 to 82.3). Conclusions: The 2018-2019 influenza vaccine is effective in preventing influenza cases in patients admitted up to week 4 of the 2018-19 season. Results are preliminary and may vary and should be re-evaluated at the end of the season.